CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
Corbus Pharmaceuticals (CRBP) announced the adjournment of its 2021 Annual Meeting to allow stockholders more time to vote on proposals, particularly Proposal 4, which seeks to double the authorized common stock from 150 million to 300 million shares. Currently, about 85% of votes cast support this proposal, but it requires a majority of outstanding shares for approval. The meeting will reconvene on June 17, 2021, at 9:00 a.m. ET. Corbus focuses on innovative medicines targeting the endocannabinoid system, with its lead candidate, lenabasum, currently being evaluated for chronic inflammatory diseases.
- Proposal 4 has about 85% support among the votes cast.
- The adjournment allows for further stockholder engagement on important matters.
- Proposal 4 has not yet received a majority of outstanding shares, delaying potential financial strategies.
Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it has adjourned its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) in order to provide stockholders additional time within which to vote on all proposals, including Proposal 4 to approve an amendment to the Company’s certificate of incorporation to increase the Company’s authorized shares of common stock from 150,000,000 to 300,000,000.
The Company believes there is significant support for Proposal 4. At the time of the Annual Meeting, approximately
The adjourned meeting will be held at 9:00 a.m. ET on Thursday, June 17, 2021 at the following url: www.viewproxy.com/corbuspharma/2021/vm. The record date for the annual meeting is March 31, 2021.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.
Lenabasum is not approved for the treatment of any indication. For more information on Corbus’ clinical programs, please visit here.
For more information, visit http://www.corbuspharma.com/, and connect with us on Twitter, LinkedIn, and Facebook.
Corbus Pharmaceuticals Contacts:
Ted Jenkins, Senior Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7745
Email: ir@corbuspharma.com
Lindsey Smith, Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7749
Email: mediainfo@corbuspharma.com
FAQ
What is the purpose of Corbus Pharmaceuticals' adjourned Annual Meeting on June 17, 2021?
What is Proposal 4 regarding Corbus Pharmaceuticals?
What percentage of votes support Proposal 4 by Corbus Pharmaceuticals?